News
Elevation Oncology LLC
ELEV · NASDAQ
Price unavailable right now.
No price history for this range.
Latest news
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders
- Press releaseBusiness Wire
ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLS, KNW, ELEV, CRKN on Behalf of Shareholders
- Press releaseBusiness Wire
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders
- Press releasePRNewswire
Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right
- News
'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill'- Bloomberg
- News
'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill' -Bloomberg
- Press releasePRNewswire
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
- Press releasePRNewswire
Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
- Press releasePRNewswire
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase
- NewsVandana Singh
Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70%
- Press releasePRNewswire
Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releasePRNewswire
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements
- Press releasePRNewswire
Elevation Oncology to Participate in Upcoming Investor Conferences
- Press releasePRNewswire
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year
- Press releasePRNewswire
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones
- NewsVandana Singh
Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise
- NewsAvi Kapoor
This Denali Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Friday
- Press releasePRNewswire
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors
- Press releasePRNewswire
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024
- Press releasePRNewswire
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference
- Press releasePRNewswire
Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releasePRNewswire
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
- Press releasePRNewswire
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- NewsAvi Kapoor
S&P 500 Surges Over 2%; Caterpillar Earnings Beat Estimates
- NewsVandana Singh
Why Is Penny Stock Elevation Oncology Trading Lower On Tuesday?
- NewsAvi Kapoor
Crude Oil Moves Higher; Yum! Brands Posts Upbeat Earnings
- NewsMichael Juliano
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing (CORRECTED)
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.